• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    MPO's 2023 Medtech Supply Chain Survey

    Exceeding Medical Device Extrusion Expectations

    Medical Device Micromolders Discuss the 'Minor Details'

    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    MPO's Most-Read Stories This Week—Sept. 30

    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman

    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device

    ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany

    Siemens Healthineers’ Magnetom Viato.Mobile Cleared by FDA
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    MPO's 2023 Medtech Supply Chain Survey

    Exceeding Medical Device Extrusion Expectations

    Medical Device Micromolders Discuss the 'Minor Details'

    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Back to School for Medical Device Cybersecurity Training

    Driving Clinical Trial Excellence to Help Study Teams Run a Faster Relay Race

    Medtech’s Supply Chain: From Disruption to Opportunity

    Are Medtech’s Mega-Deals Gone For Good?

    Will a Skilling Gap Hinder Organizational Readiness for Medtech’s New Age of AI?
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Medbio LLC

    Johari Digital Healthcare Ltd.

    Providence Enterprise USA Inc.

    LEMO USA Inc.

    NDH Medical Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    How Wearables Are Changing the Way We Collect Real-World Data in Clinical Trials

    Could Medtech Ever Stop a Hospital Killer in Their Tracks?

    A One-Stop-Shop, Turnkey Solution Is Paramount for Success

    How Additive and Subtractive Manufacturing Are Revolutionizing the Medical Device Industry

    Medical Device Commercialization: It’s What, Not When, to Transfer to Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Medbio LLC

    Johari Digital Healthcare Ltd.

    Providence Enterprise USA Inc.

    LEMO USA Inc.

    NDH Medical Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    To Clinical or Not to Clinical, That Is the Question

    ...

    To Clinical or Not to Clinical, That Is the Question
    David C. Robson, Principal, Robson Advisors05.03.18
    For simple or well-characterized medical products, it is risk-appropriate and most cost effective to immediately design and engineer the commercial configuration of the device. In these cases, the design would presumably be sufficiently “locked in,” meaning the potential for substantial oversights is virtually nil. The OEM management team could therefore decide the product could be designed to go straight into commercial manufacturing, without any interim product configurations.

    But for more complex medical devices, the company should seriously consider developing a “clinical-grade” product configuration before spending the time and money refining the myriad facets of a “commercial-grade” design. This is especially true for devices that introduce novel clinical treatments or new-to-industry functionality, or those that have not yet settled on specific treatment parameters or functional tolerance ranges.

    Whereas a commercial-grade design should satisfy all the requirements for a product to be successful (e.g., safety, effectiveness, profit margin, etc.), a clinical-grade design primarily focuses on proving the clinical function is reliable. This focus allows the sponsoring company to postpone some secondary items for later. Generally, the design will include the key components that are intended as part of the commercial solution but the design will not have been fully streamlined.

    Below are some of the reasons developing a clinical-grade or interim product configuration can be beneficial. For each of these reasons, a proper balance is required to determine how much work can be wisely postponed. Also, any components and configurations should be close approximations to the eventual commercial solution.

    Less focus on cost of goods and profit margin objectives. It goes without saying that cost of goods and resulting profit margin are critical objectives for a commercially successful product. However, tuning a product design to hit a cost model is a big undertaking. It requires consideration of part count reduction, alternate component materials or fabrication methods, streamlining of manufacturing procedures, and so on. The clinical-grade design often aims to answer foundational questions concerning how the product functions or what clinical treatment ranges will be required—cost engineering can be left for later.

    Less focus on the device’s physical size. A clinical-grade design can often relax some of the size requirements, as long as the product’s size doesn’t negatively impact the effectiveness of the device. Like the postponement of cost of goods optimization, the miniaturization process should only be pursued once the foundational functions and clinical success of the product have been confirmed.

    Less focus on some aspects of functionality and human factors. Most products have primary or foundational functions. These are the elements that need to be fully embodied and confirmed in the clinical-grade approach. Secondary items and some of the refined human factors considerations can often be postponed unless there is uncertainty about their acceptability. For instance, a solution ultimately intended for handheld use may not be as lightweight or as easy to grasp in the clinical-grade design.

    Secondary software functions can be postponed. Many medical devices employ sophisticated sensing and analysis tools to determine something. These are the critical-to-success items that the clinical-grade solution should focus upon, whereas non-critical functions should be held for later. Likewise, figuring out exactly how the screens navigate to secondary screens—language selection, for example—is work that can wait for the commercial embodiment.

    Prototype materials may be sufficient. Since a clinical-grade product is an interim stage in the development cycle, it may be justified to use prototype materials. Although they may be more expensive on a per unit basis and are often less durable, these materials can be acquired much faster and often with no capital investment.

    The development team can construct units under reduced process controls. Getting a commercial-grade manufacturing line arranged is another large undertaking. The clinical-grade approach can allow the team to insert direct inspections into the assembly process that may not be acceptable in the longer term.

    Sterilization validation could be postponed or reduced. Depending upon the product and the intended use of the clinical-grade design, it may be possible to use simplified and smaller scale sterilization methods which would otherwise be prohibitively expensive for a commercial production solution.

    Less focus on some aspects of risk management and fool-proofing. For most clinical-grade evaluation efforts, testing is done under tighter and more controlled situations. Doctors and other users of the product can receive more training and oversight than would be possible for the eventual commercial release. This may allow for lower hazards analysis scoring, which in turn may simplify some of the safety features that need to be incorporated into the clinical-grade configuration.

    The design can be purposely engineered to allow adjustments. Employing a clinical-grade approach can allow the development team to include adjustable features or functions that may be inappropriate or unwanted in the commercial solution. This can be very helpful when trying to perfect an uncertain set of human-machine interfaces or user experiences. Similarly, the ability to test different component designs or materials or collect extra data can be accommodated in the clinical-grade solution, where such adjustability would be too costly or clunky for the commercial version.

    Results can support eventual regulatory submissions. There are limitations to what kind of data the FDA or the EU will accept from product testing not done on the final design. However, in some cases risk-appropriate rationales can be made that the clinical-grade solution is sufficiently similar and can be used to support eventual submissions.

    In some cases, the clinical-grade solution could be the first commercial offering. If the device offers a novel treatment or has a strong clinical advantage over competitive solutions, there will be early adopters who will want to use it—even if it’s a little clunkier or doesn’t have a fully refined feature set. While the clinical-grade solution will not be as cost-effective as the eventual commercial solution, it could be designed and submitted for regulatory approval such that it can be offered for sale. This then gives the developing company real-world information and feedback, which can be incorporated into the larger scale commercial solution.

    It’s important to remember that converting the clinical-grade design to the commercial-grade solution should be evolutionary, not revolutionary. Many management teams of old will balk at the idea of “developing the product twice.” They may see the clinical-grade solution as an unnecessary half measure. They want the development team to develop the right product first without any mistakes. However, for complex medical systems, going straight to the commercial design increases the risk of including an “Achilles heel” in the design or misaligning the cost-function-quality balance.

    An Achilles heel in terms of a product design is an issue or error that is fundamental to the product and cannot be “designed out.” An Achilles heel issue can permanently destroy a new product line and its revenue potential. It’s much better to discover these types of problems early in the development cycle, so the team can adjust the design or, if need be, kill the project.

    The commercial solution is ideally a “tailored” version of the clinical design. Parts can be refined for injection molding and other mass production processes. The secondary control screens and software control can be added. Final verification and validation testing can then be pursued.

    If done correctly, the clinical device will have answered all the hard questions and helped to determine the exact functional ranges and tolerances. Further, the clinical solution will reveal design and durability flaws that would have been discovered during the design verification testing of the commercial configuration.

    The overall project schedule of including development of a clinical-grade solution may have a longer timeline, but the risk profile will be better controlled. Anyone that has been developing medical devices for a while knows the suffering that occurs when a product experiences a drastic “excursion” from the project plan. It can drain the life out the project team and put companies out of business. 


    David C. Robson, a principal at Robson Advisors, has spent 30 years concentrating on the development of medical devices. Seventeen of those years were spent working for a full-service product development firm where he interacted with both large and small medical device companies and reviewed statements of work and requests for quotation, wrote proposals, and negotiated hundreds of work agreements. Robson and his partners now offer product development guidance and advocacy to early-stage medical device clients.
    Related Searches
    • verification testing
    • oem
    • Sterilization
    • user
    Related Knowledge Center
    • R&D & Design
    Suggested For You
    Robson Advisors Robson Advisors
    Driving Innovation and Improving Quality with 3D Printing Driving Innovation and Improving Quality with 3D Printing
    Quality Nightmares #38: Audit Selection Quality Nightmares #38: Audit Selection
    Software Validation: How It Should Be Done Software Validation: How It Should Be Done
    FDA Authorizes First Test for Emerging Pathogen Candida Auris FDA Authorizes First Test for Emerging Pathogen Candida Auris
    FDA Releases Medical Device Safety Action Plan in Effort to Modernize Approach FDA Releases Medical Device Safety Action Plan in Effort to Modernize Approach
    FDA Clears Cantel Medical FDA Clears Cantel Medical's Automated Endoscope Reprocessor
    FDA Clears Roche FDA Clears Roche's Chlamydia and Gonorrhea Molecular Tests
    FDA Finalizes Guidances to Speed Development of Next-Generation Sequencing Based Tests FDA Finalizes Guidances to Speed Development of Next-Generation Sequencing Based Tests
    FDA FDA's Expansion of 510(k) Program Seeks to End Predicate Testing for Some Devices
    FDA Clears AI-Based Device to Detect Diabetic Retinopathy FDA Clears AI-Based Device to Detect Diabetic Retinopathy
    How Do I Serve Thee? Let Me Count the Ways How Do I Serve Thee? Let Me Count the Ways
    ‘Wait, What’s My Motivation?’ Keeping a Clear Eye on Priorities ‘Wait, What’s My Motivation?’ Keeping a Clear Eye on Priorities
    Absence Makes the Heart Grow Cold: Ensuring Regular Client/Service Provider Contact Absence Makes the Heart Grow Cold: Ensuring Regular Client/Service Provider Contact
    10 Steps to a Successful Product Development Arrangement 10 Steps to a Successful Product Development Arrangement

    Related Buyers Guide Companies

    • Robson Advisors

      ...
      David Robson, Principal 11.16.20

    • 3D/Additive Manufacturing
      Driving Innovation and Improving Quality with 3D Printing

      Driving Innovation and Improving Quality with 3D Printing

      With more than 100 FDA cleared 3D-printed devices, manufacturers should be investigating this technology.
      Eric M. Luyer, Market Research Analyst, Axendia Inc. 05.01.18

    • Software & IT
      Quality Nightmares #38: Audit Selection

      Quality Nightmares #38: Audit Selection

      Quality Nightmares offers a humorous look at the challenges faced by medtech professionals.
      MasterControl 04.27.18


    • Software & IT
      Software Validation: How It Should Be Done

      Software Validation: How It Should Be Done

      With vague guidance from FDA, device makers need to ensure they are using best practices.
      Erin Wright, Validation Product Manager, MasterControl 04.26.18

    • Diagnostics
      FDA Authorizes First Test for Emerging Pathogen Candida Auris

      FDA Authorizes First Test for Emerging Pathogen Candida Auris

      C. auris is a drug resistant yeast that can cause serious infections in hospitalized patients.
      U.S. Food and Drug Administration 04.23.18

    Loading, Please Wait..

    Trending
    • ZOLL Expands Temperature Management Portfolio To Include IQool System
    • Diabetes Innovation: MIT Engineers Unveil Implantable Device With Oxygen Factory
    • Siemens Healthineers Presents Mammomat B.brilliant
    • Danaher Names New Environmental And Applied Solutions Company Veralto
    • A New Approach To Post-Market Surveillance
    Breaking News
    • MPO's Most-Read Stories This Week—Sept. 30
    • Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    • SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    • ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany
    • Siemens Healthineers’ Magnetom Viato.Mobile Cleared by FDA
    View Breaking News >
    CURRENT ISSUE

    October 2023

    • MPO's 2023 Medtech Supply Chain Survey
    • Exceeding Medical Device Extrusion Expectations
    • Medical Device Micromolders Discuss the 'Minor Details'
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    Coating Additives Market Worth $10.5B by 2028: MarketsandMarkets
    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Sept. 30
    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    MAV Beauty Recruits Former Elizabeth Arden CEO Scott Beattie
    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Happi

    Latest Breaking News From Happi

    Is Dr. Barbara Sturm Skincare Considering a Sale?
    YSL Beauty Welcomes Five Foremost Artists to Represent New Fragrance
    Christian Siriano Appointed Olay’s First Chief Drop Officer
    Ink World

    Latest Breaking News From Ink World

    MicroDynamics, All Printing Resources Partner to Represent Veritas
    Weekly Recap: Wikoff Color, BASF, Latin America Top This Week’s Stories
    Siegwerk’s Climate Targets Validated by SBTi
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Sept. 30
    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Mergers and Acquisitions, First Solar Top This Week’s Stories
    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login